Piracetam


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Adjunct in cortical myoclonus Initial: 7.2 g/day in 2-3 divided doses; may increase by 4.8 g every 3-4 days. Max: 24 g/day in 2-3 divided doses. As a cognitive enhancer in cerebrocortical insufficiency 2.4 g daily in 2-3 divided doses. For severe cases: Up to 4.8 g daily or higher. IVAdjunct in cortical myoclonus Initial: 7.2 g/day in 2-3 divided doses; may increase by 4.8 g every 3-4 days. Max: 24 g/day in 2-3 divided doses. As a cognitive enhancer in cerebrocortical insufficiency 2.4 g daily in 2-3 divided doses. For severe cases: Up to 4.8 g daily or higher.
Administration
Oral soln: May be taken with or without food. Take w/ a glass of water or soft drink to mask bitter taste.
Contraindications
Cerebral haemorrhage, Huntington's chorea. ESRD (CrCl <20 mL/min). Pregnancy and lactation.
Special Precautions
Patient w/ history of haemorrhagic CVA, risk of bleeding (e.g. GI ulcer), underlying haemostasis disorder, severe haemorrhage; to undergo major surgery including dental surgery. Mild to moderate renal impairment. Avoid abrupt withdrawal. Patient Counselling This drug may cause hyperkinesia, somnolence and nervousness, if affected, do not drive or operate machinery.
Adverse Reactions
Nervous: Hyperkinesia, somnolence, nervousness, confusion, hallucinations, depression, asthenia, ataxia, vertigo, headache, insomnia, aggravated epilepsy, impaired balance. GI: Abdominal pain, diarrhoea, nausea, vomiting. Endocrine: Wt gain. Haematologic: Haemorrhagic disorder. Dermatologic: Angioneurotic oedema, dermatitis, pruritus, urticaria.
Drug Interactions
May cause confusion, irritability and sleep disorder w/ thyroid extract (T3 and T4). Increased pharmacological effect of anticoagulants, antiplatelet (e.g. acetylsalicylic acid).
ATC Classification
N06BX03 - piracetam ; Belongs to the class of other psychostimulants and nootropics.
Disclaimer: This information is independently developed by CIMS based on piracetam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in